Kidney Transplant | Treatment Algorithms: Claims Data Analysis | US | 2024
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, transplant patients must remain on immunosuppressive regimens for the rest of their life. Although these powerful agents provide important benefits, they are associated with many risks. This report closely examines how key immunosuppressive agents are used in newly diagnosed and recently treated kidney transplant patients.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed kidney transplant patients?
- What are the quarterly trends in prescribing among recently treated and newly diagnosed kidney transplant patients?
- How have immunosuppressive therapies been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of kidney transplant patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of kidney transplant patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates amongdrug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key drugs: Astagraf XL, Atgam, CellCept, Envarsus XR, Imuran, Lemtrada, Myfortic, Neoral, Nulojix, Prograf, Rapamune, Rituxan, Sandimmune, Simulect, Thymoglobulin, Zortress
